Ronald Witteles, MD, is a professor of cardiovascular medicine at Stanford University and co-director of the Stanford Amyloid Center and the Stanford Multidisciplinary Sarcoidosis Program

The panel focuses on recognizing extra-cardiac manifestations that often precede cardiac symptoms in ATTR-CM. Orthopedic signs—such as bilateral carpal tunnel syndrome, cervical or lumbar spinal stenosis, biceps tendon rupture, trigger finger, and recurrent joint replacements—may occur five to ten years before cardiac involvement. Neurologic and autonomic features, including peripheral neuropathy, orthostatic hypotension, constipation, diarrhea, urinary retention, and erectile dysfunction, also serve as early clues, though frequently attributed to aging or unrelated conditions. The discussion emphasizes the importance of educating clinicians across specialties to identify these signals and consider amyloidosis when patterns cluster. The panel notes that orthopedic surgeons, neurologists, primary care physicians, and geriatricians play key roles in spotting early presentations. Advanced practice providers can also help bridge communication and referral pathways. Rather than screening every patient with common conditions, the group recommends viewing these findings as risk indicators and prompting coordinated evaluation to facilitate earlier diagnosis and treatment.

Extra-Cardiac Clues and Care Team Integration for Earlier ATTR-CM Detection

The panel focuses on recognizing extra-cardiac manifestations that often precede cardiac symptoms in ATTR-CM. Orthopedic signs—such as bilateral carpal tunnel syndrome, cervical or lumbar spinal stenosis, biceps tendon rupture, trigger finger, and recurrent joint replacements—may occur five to ten years before cardiac involvement. Neurologic and autonomic features, including peripheral neuropathy, orthostatic hypotension, constipation, diarrhea, urinary retention, and erectile dysfunction, also serve as early clues, though frequently attributed to aging or unrelated conditions. The discussion emphasizes the importance of educating clinicians across specialties to identify these signals and consider amyloidosis when patterns cluster.

The panel notes that orthopedic surgeons, neurologists, primary care physicians, and geriatricians play key roles in spotting early presentations. Advanced practice providers can also help bridge communication and referral pathways. Rather than screening every patient with common conditions, the group recommends viewing these findings as risk indicators and prompting coordinated evaluation to facilitate earlier diagnosis and treatment.

Videos

The panel focuses on recognizing extra-cardiac manifestations that often precede cardiac symptoms in ATTR-CM. Orthopedic signs—such as bilateral carpal tunnel syndrome, cervical or lumbar spinal stenosis, biceps tendon rupture, trigger finger, and recurrent joint replacements—may occur five to ten years before cardiac involvement. Neurologic and autonomic features, including peripheral neuropathy, orthostatic hypotension, constipation, diarrhea, urinary retention, and erectile dysfunction, also serve as early clues, though frequently attributed to aging or unrelated conditions. The discussion emphasizes the importance of educating clinicians across specialties to identify these signals and consider amyloidosis when patterns cluster.
The panel notes that orthopedic surgeons, neurologists, primary care physicians, and geriatricians play key roles in spotting early presentations. Advanced practice providers can also help bridge communication and referral pathways. Rather than screening every patient with common conditions, the group recommends viewing these findings as risk indicators and prompting coordinated evaluation to facilitate earlier diagnosis and treatment.


Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Lipid Management in ASCVD: Current Guidelines and Key Clinical Updates

The panelists open the discussion by addressing the persistent cardiovascular risk seen in patients with established ASCVD, even with widespread statin use. The experts note that recurrent events remain common due to a combination of factors, including residual inflammatory, thrombotic, and cardiometabolic risk, along with insufficient LDL-C lowering. 

Data show that many secondary prevention patients still have LDL-C levels above 70 mg/dL, and therapy intensification is infrequent over time. The panelists emphasize that cumulative LDL-C exposure is a critical determinant of ongoing atherosclerotic progression—patients who experience a cardiac event often carry a lifelong burden of atherogenic exposure and are at highest risk shortly after their initial event. Many discontinue lipid-lowering therapy once they feel better, losing long-term benefit. 

The discussion concludes that sustained, aggressive LDL-C reduction beyond the acute phase is essential to alter the trajectory of recurrent cardiovascular risk in ASCVD management.

This program brings together leading experts to discuss evolving strategies for reducing recurrent cardiovascular risk in patients with ASCVD, emphasizing the importance of cumulative LDL-C exposure and the need for earlier, more intensive lipid lowering. The panel explores current guidelines, emerging data from recent trials, and practical approaches to integrating PCSK9-targeting therapies to improve long-term adherence, access, and outcomes in secondary prevention

Exploration of combination and sequencing strategies for patients with refractory or advanced disease to achieve comprehensive disease control.

Application of S1P Receptor Agonists for Treating IBD

The Peers & Perspectives series episode on Optimizing Therapeutic Strategies in Inflammatory Bowel Disease opens with a discussion on redefining remission. Traditional endpoints, such as symptom improvement, are increasingly being supplemented with objective measures like endoscopic and histologic healing to better capture treatment effectiveness. The conversation highlights how deeper healing correlates with sustained remission and improved quality of life, while also addressing the practical challenges of implementing these advanced endpoints in clinical practice—balancing diagnostic precision, resource availability, and patient accessibility.

Building on this foundation, the program transitions to an analysis of early intervention strategies and their impact on disease trajectory. Recent research underscores that initiating advanced therapy earlier in the disease course can significantly enhance both short- and long-term outcomes. The discussion delves into the importance of identifying high-risk individuals before the onset of severe symptoms and tailoring therapy based on disease phenotype, risk profile, and treatment goals. Comparisons are drawn between established and emerging agents—including biologics, JAK inhibitors, S1P receptor modulators, and IL-23 inhibitors—to help clinicians navigate evolving treatment algorithms with confidence.

In its closing section, the program looks ahead to the future of IBD management, focusing on the role of predictive medicine and the integration of novel biomarkers, genetic insights, and multi-omics data. These tools are expected to transform how clinicians diagnose, stratify, and monitor patients—enabling more personalized, preventative, and data-driven approaches to care. The discussion concludes with a forward-looking perspective on clinical research priorities, emphasizing the need for continued innovation in treatment endpoints, combination therapy trials, and patient-centered outcome measures that define the next generation of IBD care.

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

In this discussion, the panelists explore the identification of risk factors and the broader impact of psoriatic disease. The experts explain that certain clinical features—such as scalp and nail involvement, higher body surface area, and disease severity—are associated with an increased likelihood of developing psoriatic arthritis (PsA). They also note that modifiable factors like obesity, smoking, and metabolic syndrome further contribute to this risk. While genetics play a role, the experts emphasize the importance of addressing lifestyle factors and systemic inflammation early. The conversation highlights that psoriasis should be recognized as a systemic disease rather than one limited to the skin. By identifying high-risk patients and initiating systemic therapy sooner, clinicians can better manage inflammation, improve quality of life, and potentially reduce PsA progression. The panel underscores the importance of patient education and multidisciplinary care to optimize outcomes.

Identifying Risk and Recognizing Impact in Psoriatic Disease”

Identifying Risk and Recognizing Impact in Psoriatic Disease

Cumulative LDL-C Exposure and the Persistent Challenge of Recurrent ASCVD

In this opening segment, the experts introduce this series focused on rethinking treatment goals in psoriasis. The discussion begins with an overview of the strong pathophysiologic link between psoriasis and psoriatic arthritis (PsA). The panelists explain that both conditions share an IL-23/Th17 inflammatory pathway, where activation of Th17 cells leads to cytokine release—such as IL-17A, IL-17F, and IL-22—driving inflammation in both skin and joints. This common mechanism helps explain why approximately one-third of patients with psoriasis eventually develop PsA. The experts emphasize that recognizing this overlap supports the need for therapeutic strategies that target shared cytokines early in the disease course. By addressing systemic inflammation before joint damage occurs, clinicians may be able to modify disease progression and improve long-term outcomes for patients with psoriatic disease.

Understanding of the Pathophysiologic Connection Between Psoriasis and Psoriatic Arthritis (PsA)

The panel opens by outlining the significant clinical burden of ATTR-CM. Patients often initially present with atrial arrhythmias or conduction abnormalities before developing heart failure, which commonly manifests first as exercise intolerance. Without treatment, the disease follows a progressive course that impacts both patients and caregivers, many of whom are unfamiliar with amyloidosis at diagnosis. The discussion highlights notable delays in identifying hereditary ATTR-CM, particularly among Black and Caribbean patients with the V142I variant, emphasizing the need for improved community and provider awareness.
The conversation then shifts to trends in diagnosis. While recognition of ATTR-CM has increased and patients are being diagnosed earlier—with outcomes improving when therapy is initiated sooner—significant barriers remain. A major challenge is persistent misperception of ATTR-CM as rare. The panel stresses reframing heart failure with preserved ejection fraction as a syndrome requiring etiologic evaluation and encourages clinicians to consider ATTR-CM in older patients with increased ventricular wall thickness, prompting timely, appropriate diagnostic workup.


Clinical Burden and Barriers to Early Diagnosis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)”

Analysis of how to balance established therapies such as anti-TNFs and immunomodulators with novel agents like JAK inhibitors, S1P modulators, and IL-23 inhibitors.

Available Therapy Options for IBD and Their Place in the Current Treatment Setting

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Medical Sisterhood: Balance and Boundaries in the Holiday Season, With Angela Lamb, MD

Paul Whelton, MD, is a Show Chwan Health System Endowed Chair in Public Health at Tulane University.

Whelton discusses the successful results of an open-label extension investigating GMRx2, a novel triple combination pill for hypertension.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Triple Combination Therapy Superior to Single in Lowering Blood Pressure, With Paul Whelton, MD

Patricia Stewart, MD: Mississippi Asthma & Allergy Center  

Children with HAE often face delayed or inconsistent emergency care, with clinicians citing limited condition-specific knowledge as a key contributor.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Emergency Care Still Falling Short for Children With HAE, With Patricia Stewart, MD

Naim Alkhouri, MD, is Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio.

Alkhouri explains findings from the phase 2 WAYFIND trial suggesting the potential of semaglutide and cilofexor/firsocostat for MASH cirrhosis.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

WAYFIND: Exploring Combination Therapy for MASH Cirrhosis, With Naim Alkhouri, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Articles

The FDA has approved RNA interference therapeutic plozasiran for the treatment of familial chylomicronemia syndrome.

Dyslipidemia

FDA News

FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome

Juan Badimon, PhD, is a professor of medicine and the director of the Atherothrombosis Research Unit at the Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai.

Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

SOTA-P-CARDIA: Sotagliflozin Exhibits Antithrombotic Effects in Patients with HFpEF, With Juan Badimon, PhD

New qualitative findings reveal the underrecognized psychosocial burdens facing children with HAE and the unmet needs shaping their care.

Latest News

Extra-Cardiac Clues and Care Team Integration for Earlier ATTR-CM Detection

Lipid Management in ASCVD: Current Guidelines and Key Clinical Updates

Application of S1P Receptor Agonists for Treating IBD

Identifying Risk and Recognizing Impact in Psoriatic Disease

Cumulative LDL-C Exposure and the Persistent Challenge of Recurrent ASCVD